Cardiometabolic Comorbidities in Patients With Psoriasis: Focusing on Risk, Biological Therapy, and Pathogenesis

Psoriasis is a chronic inflammatory disease characterized by erythematous scaly plaques, accompanied by systemic damage that leads to the development of multiple comorbidities. In particular, the association between psoriasis and cardiometabolic comorbidities, including cardiovascular diseases (CVDs...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jiangluyi Cai, Lian Cui, Yu Wang, Ying Li, Xilin Zhang, Yuling Shi
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	psoriasis biologics cardiovascular disease diabetes mellitus obesity metabolic syndrome Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/29eef2a332c8487a99e5fcd26e4944c8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:29eef2a332c8487a99e5fcd26e4944c8
record_format	dspace
spelling	oai:doaj.org-article:29eef2a332c8487a99e5fcd26e4944c82021-11-04T07:18:33ZCardiometabolic Comorbidities in Patients With Psoriasis: Focusing on Risk, Biological Therapy, and Pathogenesis1663-981210.3389/fphar.2021.774808https://doaj.org/article/29eef2a332c8487a99e5fcd26e4944c82021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fphar.2021.774808/fullhttps://doaj.org/toc/1663-9812Psoriasis is a chronic inflammatory disease characterized by erythematous scaly plaques, accompanied by systemic damage that leads to the development of multiple comorbidities. In particular, the association between psoriasis and cardiometabolic comorbidities, including cardiovascular diseases (CVDs), obesity, diabetes mellitus, and metabolic syndrome, has been verified in a considerable number of clinical trials. Moreover, the increased risk of cardiometabolic comorbidities positively correlates with psoriasis severity. Biologic therapy targeting inflammatory pathways or cytokines substantially improves the life quality of psoriasis patients and may affect cardiometabolic comorbidities by reducing their incidences. In this review, we focus on exploring the association between cardiometabolic comorbidities and psoriasis, and emphasize the benefits and precautions of biologic therapy in the management of psoriasis with cardiometabolic comorbidities. The pathogenic mechanisms of cardiometabolic comorbidities in psoriasis patients involve common genetic factors, lipid metabolism, insulin resistance, and shared inflammatory pathways such as tumor necrosis factor-α and interleukin-23/Th-17 pathways.Jiangluyi CaiJiangluyi CaiLian CuiLian CuiYu WangYu WangYing LiYing LiXilin ZhangXilin ZhangYuling ShiYuling ShiFrontiers Media S.A.articlepsoriasisbiologicscardiovascular diseasediabetes mellitusobesitymetabolic syndromeTherapeutics. PharmacologyRM1-950ENFrontiers in Pharmacology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	psoriasis biologics cardiovascular disease diabetes mellitus obesity metabolic syndrome Therapeutics. Pharmacology RM1-950
spellingShingle	psoriasis biologics cardiovascular disease diabetes mellitus obesity metabolic syndrome Therapeutics. Pharmacology RM1-950 Jiangluyi Cai Jiangluyi Cai Lian Cui Lian Cui Yu Wang Yu Wang Ying Li Ying Li Xilin Zhang Xilin Zhang Yuling Shi Yuling Shi Cardiometabolic Comorbidities in Patients With Psoriasis: Focusing on Risk, Biological Therapy, and Pathogenesis
description	Psoriasis is a chronic inflammatory disease characterized by erythematous scaly plaques, accompanied by systemic damage that leads to the development of multiple comorbidities. In particular, the association between psoriasis and cardiometabolic comorbidities, including cardiovascular diseases (CVDs), obesity, diabetes mellitus, and metabolic syndrome, has been verified in a considerable number of clinical trials. Moreover, the increased risk of cardiometabolic comorbidities positively correlates with psoriasis severity. Biologic therapy targeting inflammatory pathways or cytokines substantially improves the life quality of psoriasis patients and may affect cardiometabolic comorbidities by reducing their incidences. In this review, we focus on exploring the association between cardiometabolic comorbidities and psoriasis, and emphasize the benefits and precautions of biologic therapy in the management of psoriasis with cardiometabolic comorbidities. The pathogenic mechanisms of cardiometabolic comorbidities in psoriasis patients involve common genetic factors, lipid metabolism, insulin resistance, and shared inflammatory pathways such as tumor necrosis factor-α and interleukin-23/Th-17 pathways.
format	article
author	Jiangluyi Cai Jiangluyi Cai Lian Cui Lian Cui Yu Wang Yu Wang Ying Li Ying Li Xilin Zhang Xilin Zhang Yuling Shi Yuling Shi
author_facet	Jiangluyi Cai Jiangluyi Cai Lian Cui Lian Cui Yu Wang Yu Wang Ying Li Ying Li Xilin Zhang Xilin Zhang Yuling Shi Yuling Shi
author_sort	Jiangluyi Cai
title	Cardiometabolic Comorbidities in Patients With Psoriasis: Focusing on Risk, Biological Therapy, and Pathogenesis
title_short	Cardiometabolic Comorbidities in Patients With Psoriasis: Focusing on Risk, Biological Therapy, and Pathogenesis
title_full	Cardiometabolic Comorbidities in Patients With Psoriasis: Focusing on Risk, Biological Therapy, and Pathogenesis
title_fullStr	Cardiometabolic Comorbidities in Patients With Psoriasis: Focusing on Risk, Biological Therapy, and Pathogenesis
title_full_unstemmed	Cardiometabolic Comorbidities in Patients With Psoriasis: Focusing on Risk, Biological Therapy, and Pathogenesis
title_sort	cardiometabolic comorbidities in patients with psoriasis: focusing on risk, biological therapy, and pathogenesis
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/29eef2a332c8487a99e5fcd26e4944c8
work_keys_str_mv	AT jiangluyicai cardiometaboliccomorbiditiesinpatientswithpsoriasisfocusingonriskbiologicaltherapyandpathogenesis AT jiangluyicai cardiometaboliccomorbiditiesinpatientswithpsoriasisfocusingonriskbiologicaltherapyandpathogenesis AT liancui cardiometaboliccomorbiditiesinpatientswithpsoriasisfocusingonriskbiologicaltherapyandpathogenesis AT liancui cardiometaboliccomorbiditiesinpatientswithpsoriasisfocusingonriskbiologicaltherapyandpathogenesis AT yuwang cardiometaboliccomorbiditiesinpatientswithpsoriasisfocusingonriskbiologicaltherapyandpathogenesis AT yuwang cardiometaboliccomorbiditiesinpatientswithpsoriasisfocusingonriskbiologicaltherapyandpathogenesis AT yingli cardiometaboliccomorbiditiesinpatientswithpsoriasisfocusingonriskbiologicaltherapyandpathogenesis AT yingli cardiometaboliccomorbiditiesinpatientswithpsoriasisfocusingonriskbiologicaltherapyandpathogenesis AT xilinzhang cardiometaboliccomorbiditiesinpatientswithpsoriasisfocusingonriskbiologicaltherapyandpathogenesis AT xilinzhang cardiometaboliccomorbiditiesinpatientswithpsoriasisfocusingonriskbiologicaltherapyandpathogenesis AT yulingshi cardiometaboliccomorbiditiesinpatientswithpsoriasisfocusingonriskbiologicaltherapyandpathogenesis AT yulingshi cardiometaboliccomorbiditiesinpatientswithpsoriasisfocusingonriskbiologicaltherapyandpathogenesis
_version_	1718445008321773568

Cardiometabolic Comorbidities in Patients With Psoriasis: Focusing on Risk, Biological Therapy, and Pathogenesis

Ejemplares similares